Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-κb decoy oligonucleotides

American Journal of Surgery

Volumn 197, Issue 6, 2009, Pages 797-805

  Xiang, Jun Ying ^a   Wu, Li Guo ^a   Huang, Xiao Li ^a   Zhang, Meng ^a   Pen, Lan ^a   Ouyan, Qin ^a   Gan, Hua Tian ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Dextran sulfate sodium induced colitis; Nuclear factor B decoy ODNs; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MYELOPEROXIDASE; OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA BINDING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; DEXTRAN SULFATE; FEMALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES;

EID: 66149083594     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.04.012     Document Type: Article

References (45)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Sands B.E. Therapy of inflammatory bowel disease. Gastroenterology 118 (2000) S68-S82
3. Sandborn W.J., and Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122 (2002) 1592-1608
4. Papadakis K.A., and Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51 (2000) 289-298
5. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J Surg 22 (1998) 382-389
6. Stevens C., Walz G., Singaram C., et al. Tumor necrosis factor-a, interleukin-1b, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37 (1992) 818-826
7. Ligumsky M., Simon P.L., Karmeli F., et al. Role of interleukin-1 on inflammatory bowel disease. Gut 31 (1990) 686-689
8. Blackwell T.S., and Christman J.W. The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 17 (1997) 3-9
9. Tak P.P., and Firestein G.S. NF-κB: a key role in inflammatory disease. J Clin Invest 107 (2001) 7-11
10. Baeuerle P., and Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 12 (1994) 141-153
11. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14 (1996) 649-683
12. Finco T., and Baldwin Jr. A.S. Mechanistic aspects of NF-κB regulation: the emerging role of phosphorylation and proteolysis. Immunity 3 (1995) 263-272
13. Rogler G., Brand K., Vogl D., et al. Nuclear factor-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115 (1998) 537-569
14. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor-κB in inflammatory bowel disease. Gut 42 (1998) 477-484
15. Neurath M.F., Fuss I., Schurmann G., et al. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease. Ann NY Acad Sci 859 (1998) 149-159
16. Neurath M.F., Pettersson S., Meyer Z.U.M., et al. Local administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2 (1996) 998-1004
17. Morishita R., Sugimoto T., Aoki M., et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3 (1997) 894-899
18. Morishita R., Tomita N., Kaneda Y., et al. Molecular therapy to inhibit NF-κB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 4 (2004) 139-146
19. Morishita R., Higaki J., Tomita N., et al. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 82 (1998) 1023-1028
20. Tomita N., Morishita R., Tomita S., et al. Transcription factor decoy for NF-κB inhibits TNF-a-induced cytokine and adhesion molecule expression in vivo. Gene Ther 7 (2000) 1326-1332
21. Cao C.C., Ding X.Q., Ou Z.L., et al. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 65 (2004) 834-845
22. Tomita T., Takeuchi E., Tomita N., et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42 (1999) 2532-2542
23. Fichtner-Feigl S., Fuss I.J., Preiss J.C., et al. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides. J Clin Invest 115 (2005) 3057-3071
24. De Vry Christopher G., Prasad S., Komuves L., et al. Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 56 (2007) 524-533
25. Dajee M., Muchamuel T., Schryver B., et al. Blockade of experimental atopic dermatitis via topical NF-κB decoy oligonucleotide. J Invest Dermatol 126 (2006) 1792-1803
26. Yamasaki K., Asai T., Shimizu M., et al. Inhibition of NF-κB activation using cis-element "decoy" of NF-κB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10 (2003) 356-364
27. Murthy S.N.S., Cooper H.S., Shim H., et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38 (1993) 1722-1734
28. Cooper H.S., Murthy S.N.S., Shah R.S., et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69 (1993) 238-249
29. ten Hove T., van den Blink B., Pronk I., et al. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50 (2002) 507-512
30. Gan H.T., Chen Y.Q., and Ouyan Q. Sulfasalazine inhibits activation of nuclear factor-kB in patients with ulcerative colitis. J Gastroenterol Hepatol 20 (2005) 1016-1024
31. Cooper Jr. J.A.D., Parks J.M., Carcelen R., et al. Attenuation of interleukin-8 production by inhibiting nuclear factor-κB translocation using decoy oligonucleotides. Biochem Pharmacol 59 (2000) 605-613
32. Rioja I., Bush K.A., Buckton J.B., et al. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 137 (2004) 65-73
33. Okayasu I., Hatakeyama S., Yamada M., et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98 (1990) 694-702
34. Cho J.Y., Chang J.H., Lee S.K., et al. Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of β-caryophyllene, a sesquiterpene. Life Sci 80 (2007) 932-939
35. Ohkawarai T., Takedai H., Kato K., et al. Polaprezinc (N-(3-aminopropionyl)-L-histidinato zinc) ameliorates dextran sulfate sodium-induced colitis in mice. Scand J Gastroenterol 40 (2005) 1321-1327
36. Woo P. Cytokine polymorphisms and inflammation. Clin Exp Rheumatol 18 (2000) 767-771
37. Mantovani A., Muzio M., Garlanda C., et al. Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found Symp 234 (2001) 120-131
38. Thukral C., Cheifetz A., and Peppercorn M.A. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 16 (2006) 2059-2065
39. Ogata H., and Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 9 (2003) 1107-1113
40. Nakamura K., Honda K., Mizutani T., et al. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 12 (2006) 4628-4635
41. Aberra F.N., and Lichtenstein G.R. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 35 (2006) 821-836
42. Feagan B.G., Reinisch W., Rutgeerts P., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 102 (2007) 794-802
43. Desmet C., Gosset P., Pajak B., et al. Selective blockade of NF-κB activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 173 (2004) 5766-5775
44. Blumberg R.S., Saubermann L.J., and Strober W. Animal models of mucosal inflmmation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11 (1999) 648-656
45. Elson C.O., Cong Y., McCracken V.J., et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206 (2005) 260-276